newsfilter
← Latest News
Business Wire·

KalVista Pharmaceuticals Presents New Data at the European Academy of Allergy and Clinical Immunology Congress 2025 on the Efficacy of Sebetralstat for the On-demand Treatment of HAE Attacks Among Patients Receiving Long-Term Prophylaxis

–Real-world data highlight significant challenges with LTP adherence, and ongoing reliance on on-demand medications– –In KONFIDENT-S, oral sebetralstat delivered rapid, consistent relief for breakthrough attacks,